Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Preoperative visual evoked potential in the prediction of visual outcome after pituitary macroadenomas surgery.

Taghvaei M, Sadrehosseini SM, Ostadrahimi N, Sarraf P, Zeinalizadeh M.

Pituitary. 2019 May 28. doi: 10.1007/s11102-019-00969-5. [Epub ahead of print]

PMID:
31140112
2.

The Neuromodulatory Effects of ω-3 Fatty Acids and Nano-Curcumin on the COX-2/ iNOS Network in Migraines: A Clinical Trial Study from Gene Expression to Clinical Symptoms.

Abdolahi M, Jafarieh A, Sarraf P, Sedighiyan M, Yousefi A, Tafakhori A, Abdollahi H, Salehinia F, Djalali M.

Endocr Metab Immune Disord Drug Targets. 2019 Feb 12. doi: 10.2174/1871530319666190212170140. [Epub ahead of print]

PMID:
30760195
3.

Effect of coenzyme Q10 supplementation on clinical features of migraine: a systematic review and dose-response meta-analysis of randomized controlled trials.

Parohan M, Sarraf P, Javanbakht MH, Ranji-Burachaloo S, Djalali M.

Nutr Neurosci. 2019 Feb 6:1-8. doi: 10.1080/1028415X.2019.1572940. [Epub ahead of print]

PMID:
30727862
4.

Push-out bond strength of calcium-silicate cements following Er:YAG and diode laser irradiation of root dentin.

Mohammadian F, Soufi S, Dibaji F, Sarraf P, Chiniforush N, Kharrazifard MJ.

Lasers Med Sci. 2019 Feb;34(1):201-207. doi: 10.1007/s10103-018-02705-0. Epub 2019 Jan 4.

PMID:
30607722
5.

A Novel Combination of ω-3 Fatty Acids and Nano-Curcumin Modulates Interleukin-6 Gene Expression and High Sensitivity C-reactive Protein Serum Levels in Patients with Migraine: A Randomized Clinical Trial Study.

Abdolahi M, Sarraf P, Javanbakht MH, Honarvar NM, Hatami M, Soveyd N, Tafakhori A, Sedighiyan M, Djalali M, Jafarieh A, Masoudian Y, Djalali M.

CNS Neurol Disord Drug Targets. 2018;17(6):430-438. doi: 10.2174/1871527317666180625101643.

PMID:
29938621
6.

Molecular mechanisms of omega-3 fatty acids in the migraine headache.

Soveyd N, Abdolahi M, Bitarafan S, Tafakhori A, Sarraf P, Togha M, Okhovat AA, Hatami M, Sedighiyan M, Djalali M, Mohammadzadeh Honarvar N.

Iran J Neurol. 2017 Oct 7;16(4):210-217. Review.

7.

Translation, Cross-Cultural Adaptation, Validation and Reliability of the Northwestern Dysphagia Patient Check Sheet (NDPCS) in Iran.

Bakhtiyari J, Salmani M, Noruzi R, Sarraf P, Barzegar E, Mirmohammadkhani M.

Iran J Otorhinolaryngol. 2018 Mar;30(97):97-101.

8.

Safety and Efficacy of Nanocurcumin as Add-On Therapy to Riluzole in Patients With Amyotrophic Lateral Sclerosis: A Pilot Randomized Clinical Trial.

Ahmadi M, Agah E, Nafissi S, Jaafari MR, Harirchian MH, Sarraf P, Faghihi-Kashani S, Hosseini SJ, Ghoreishi A, Aghamollaii V, Hosseini M, Tafakhori A.

Neurotherapeutics. 2018 Apr;15(2):430-438. doi: 10.1007/s13311-018-0606-7.

9.

Worldwide prevalence of familial multiple sclerosis: A systematic review and meta-analysis.

Harirchian MH, Fatehi F, Sarraf P, Honarvar NM, Bitarafan S.

Mult Scler Relat Disord. 2018 Feb;20:43-47. doi: 10.1016/j.msard.2017.12.015. Epub 2017 Dec 24. Review.

PMID:
29291483
10.

The Combined Effects of ω -3 Fatty Acids and Nano-Curcumin Supplementation on Intercellular Adhesion Molecule-1 (ICAM-1) Gene Expression and Serum Levels in Migraine Patients.

Soveyd N, Abdolahi M, Djalali M, Hatami M, Tafakhori A, Sarraf P, Honarvar NM.

CNS Neurol Disord Drug Targets. 2018 Mar 13;16(10):1120-1126. doi: 10.2174/1871527317666171213154749.

PMID:
29237386
11.

The Effect of BC Sealer, AH-Plus and Dorifill on Push-out Bond Strength of Fiber Post.

Dibaji F, Mohammadi E, Farid F, Mohammadian F, Sarraf P, Kharrazifard MJ.

Iran Endod J. 2017 Fall;12(4):443-448. doi: 10.22037/iej.v12i4.15863.

12.

The first attack of multiple sclerosis presented immediately after voluntary and intensive weight loss: A case series.

Bitarafan S, Amani K, Sahraian MA, Sarraf P, Soltani D, Moghadasi AN, Harirchian MH.

Iran J Neurol. 2017 Jan 5;16(1):41-42. No abstract available.

13.

Phylogeny and biogeography of Maclura (Moraceae) and the origin of an anachronistic fruit.

Gardner EM, Sarraf P, Williams EW, Zerega NJC.

Mol Phylogenet Evol. 2017 Dec;117:49-59. doi: 10.1016/j.ympev.2017.06.021. Epub 2017 Jul 8.

PMID:
28698111
14.

Cerebral Venous Sinus Thrombosis May Follow a Seasonal Pattern.

Salehi G, Sarraf P, Fatehi F.

J Stroke Cerebrovasc Dis. 2016 Dec;25(12):2838-2843. doi: 10.1016/j.jstrokecerebrovasdis.2016.07.045. Epub 2016 Aug 22.

PMID:
27562710
15.

Evaluation of the Diode laser (810nm,980nm) on dentin tubule diameter following internal bleaching.

Kiomarsi N, Salim S, Sarraf P, Javad-Kharazifard M, Chiniforush N.

J Clin Exp Dent. 2016 Jul 1;8(3):e241-5. doi: 10.4317/jced.52666. eCollection 2016 Jul.

16.

Nutritional Aspects of Treatment in Epileptic Patients.

Soltani D, Ghaffar Pour M, Tafakhori A, Sarraf P, Bitarafan S.

Iran J Child Neurol. 2016 Summer;10(3):1-12. Review.

17.

Effects of early intervention of swallowing therapy on recovery from dysphagia following stroke.

Bakhtiyari J, Sarraf P, Nakhostin-Ansari N, Tafakhori A, Logemann J, Faghihzadeh S, Harirchian MH.

Iran J Neurol. 2015 Jul 6;14(3):119-24.

18.

Application of ultrasound elastography for determining carpal tunnel syndrome severity.

Ghajarzadeh M, Dadgostar M, Sarraf P, Emami-Razavi SZ, Miri S, Malek M.

Jpn J Radiol. 2015 May;33(5):273-8. doi: 10.1007/s11604-015-0416-3. Epub 2015 Apr 17.

PMID:
25895157
19.

Epileptic syndromes: From clinic to genetic.

Tafakhori A, Aghamollaii V, Faghihi-Kashani S, Sarraf P, Habibi L.

Iran J Neurol. 2015 Jan 5;14(1):1-7. Review.

20.

Relationship between Sleep Quality and Quality of Life in Patients with Multiple Sclerosis.

Sarraf P, Azizi S, Moghaddasi AN, Sahraian MA, Tafakhori A, Ghajarzadeh M.

Int J Prev Med. 2014 Dec;5(12):1582-6.

21.

The best cutoff point for median nerve cross sectional area at the level of carpal tunnel inlet.

Sarraf P, Malek M, Ghajarzadeh M, Miri S, Parhizgar E, Emami-Razavi SZ.

Acta Med Iran. 2014;52(8):613-8.

22.

Creutzfeldt-Jacob disease: a case report.

Sarraf P, Ghajarzadeh M, Salarian B.

Acta Med Iran. 2014;52(6):488-9.

23.

Pharmaceutical forecasting: throwing darts?

Cha M, Rifai B, Sarraf P.

Nat Rev Drug Discov. 2013 Oct;12(10):737-8. doi: 10.1038/nrd4127. No abstract available.

PMID:
24080692
24.

Non-crystalline and crystalline rheumatic disorders in chronic kidney disease.

Sarraf P, Kay J, Reginato AM.

Curr Rheumatol Rep. 2008 Jul;10(3):235-48. Review.

PMID:
18638433
25.

Wegener's granulomatosis: is biologic therapy useful?

Sarraf P, Kay J, Friday RP, Reginato AM.

Curr Rheumatol Rep. 2006 Aug;8(4):303-11. Review.

PMID:
16839510
26.

Pathogenesis of Wegener's granulomatosis: current concepts.

Sarraf P, Sneller MC.

Expert Rev Mol Med. 2005 May 13;7(8):1-19. Review.

PMID:
15890083
27.

Targeted elimination of peroxisome proliferator-activated receptor gamma in beta cells leads to abnormalities in islet mass without compromising glucose homeostasis.

Rosen ED, Kulkarni RN, Sarraf P, Ozcan U, Okada T, Hsu CH, Eisenman D, Magnuson MA, Gonzalez FJ, Kahn CR, Spiegelman BM.

Mol Cell Biol. 2003 Oct;23(20):7222-9.

28.

Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer: a phase II study.

Burstein HJ, Demetri GD, Mueller E, Sarraf P, Spiegelman BM, Winer EP.

Breast Cancer Res Treat. 2003 Jun;79(3):391-7.

PMID:
12846423
29.

Peroxisome proliferator-activated receptor gamma-mediated differentiation: a mutation in colon cancer cells reveals divergent and cell type-specific mechanisms.

Gupta RA, Sarraf P, Mueller E, Brockman JA, Prusakiewicz JJ, Eng C, Willson TM, DuBois RN.

J Biol Chem. 2003 Jun 20;278(25):22669-77. Epub 2003 Feb 18.

30.

Peroxisome proliferator-activated receptor gamma and transforming growth factor-beta pathways inhibit intestinal epithelial cell growth by regulating levels of TSC-22.

Gupta RA, Sarraf P, Brockman JA, Shappell SB, Raftery LA, Willson TM, DuBois RN.

J Biol Chem. 2003 Feb 28;278(9):7431-8. Epub 2002 Dec 4.

31.

APC-dependent suppression of colon carcinogenesis by PPARgamma.

Girnun GD, Smith WM, Drori S, Sarraf P, Mueller E, Eng C, Nambiar P, Rosenberg DW, Bronson RT, Edelmann W, Kucherlapati R, Gonzalez FJ, Spiegelman BM.

Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13771-6. Epub 2002 Oct 7.

32.

Genetic analysis of adipogenesis through peroxisome proliferator-activated receptor gamma isoforms.

Mueller E, Drori S, Aiyer A, Yie J, Sarraf P, Chen H, Hauser S, Rosen ED, Ge K, Roeder RG, Spiegelman BM.

J Biol Chem. 2002 Nov 1;277(44):41925-30. Epub 2002 Aug 27.

33.

Target genes of peroxisome proliferator-activated receptor gamma in colorectal cancer cells.

Gupta RA, Brockman JA, Sarraf P, Willson TM, DuBois RN.

J Biol Chem. 2001 Aug 10;276(32):29681-7. Epub 2001 Jun 7.

34.

Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer.

Mueller E, Smith M, Sarraf P, Kroll T, Aiyer A, Kaufman DS, Oh W, Demetri G, Figg WD, Zhou XP, Eng C, Spiegelman BM, Kantoff PW.

Proc Natl Acad Sci U S A. 2000 Sep 26;97(20):10990-5.

35.

PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected].

Kroll TG, Sarraf P, Pecciarini L, Chen CJ, Mueller E, Spiegelman BM, Fletcher JA.

Science. 2000 Aug 25;289(5483):1357-60. Erratum in: Science 2000 Sep 1;289(5484):1474.

36.

Over-representation of PPARgamma sequence variants in sporadic cases of glioblastoma multiforme: preliminary evidence for common low penetrance modifiers for brain tumour risk in the general population.

Zhou XP, Smith WM, Gimm O, Mueller E, Gao X, Sarraf P, Prior TW, Plass C, von Deimling A, Black PM, Yates AJ, Eng C.

J Med Genet. 2000 Jun;37(6):410-4.

37.

Degradation of the peroxisome proliferator-activated receptor gamma is linked to ligand-dependent activation.

Hauser S, Adelmant G, Sarraf P, Wright HM, Mueller E, Spiegelman BM.

J Biol Chem. 2000 Jun 16;275(24):18527-33.

38.

PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro.

Rosen ED, Sarraf P, Troy AE, Bradwin G, Moore K, Milstone DS, Spiegelman BM, Mortensen RM.

Mol Cell. 1999 Oct;4(4):611-7.

39.

Loss-of-function mutations in PPAR gamma associated with human colon cancer.

Sarraf P, Mueller E, Smith WM, Wright HM, Kum JB, Aaltonen LA, de la Chapelle A, Spiegelman BM, Eng C.

Mol Cell. 1999 Jun;3(6):799-804.

40.

Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma.

Demetri GD, Fletcher CD, Mueller E, Sarraf P, Naujoks R, Campbell N, Spiegelman BM, Singer S.

Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3951-6.

41.

DEF-1, a novel Src SH3 binding protein that promotes adipogenesis in fibroblastic cell lines.

King FJ, Hu E, Harris DF, Sarraf P, Spiegelman BM, Roberts TM.

Mol Cell Biol. 1999 Mar;19(3):2330-7.

42.

Rates of ubiquitin conjugation increase when muscles atrophy, largely through activation of the N-end rule pathway.

Solomon V, Baracos V, Sarraf P, Goldberg AL.

Proc Natl Acad Sci U S A. 1998 Oct 13;95(21):12602-7.

43.

Differentiation and reversal of malignant changes in colon cancer through PPARgamma.

Sarraf P, Mueller E, Jones D, King FJ, DeAngelo DJ, Partridge JB, Holden SA, Chen LB, Singer S, Fletcher C, Spiegelman BM.

Nat Med. 1998 Sep;4(9):1046-52.

PMID:
9734398
44.

Association between secondary flow in models of the aorto-celiac junction and subendothelial macrophages in the normal rabbit.

Malinauskas RA, Sarraf P, Barber KM, Truskey GA.

Atherosclerosis. 1998 Sep;140(1):121-34.

PMID:
9733223
45.

Terminal differentiation of human breast cancer through PPAR gamma.

Mueller E, Sarraf P, Tontonoz P, Evans RM, Martin KJ, Zhang M, Fletcher C, Singer S, Spiegelman BM.

Mol Cell. 1998 Feb;1(3):465-70.

46.

Nutritional and insulin regulation of fatty acid synthetase and leptin gene expression through ADD1/SREBP1.

Kim JB, Sarraf P, Wright M, Yao KM, Mueller E, Solanes G, Lowell BB, Spiegelman BM.

J Clin Invest. 1998 Jan 1;101(1):1-9.

47.

Functional antagonism between CCAAT/Enhancer binding protein-alpha and peroxisome proliferator-activated receptor-gamma on the leptin promoter.

Hollenberg AN, Susulic VS, Madura JP, Zhang B, Moller DE, Tontonoz P, Sarraf P, Spiegelman BM, Lowell BB.

J Biol Chem. 1997 Feb 21;272(8):5283-90.

48.

Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor.

Tontonoz P, Singer S, Forman BM, Sarraf P, Fletcher JA, Fletcher CD, Brun RP, Mueller E, Altiok S, Oppenheim H, Evans RM, Spiegelman BM.

Proc Natl Acad Sci U S A. 1997 Jan 7;94(1):237-41.

49.

Multiple cytokines and acute inflammation raise mouse leptin levels: potential role in inflammatory anorexia.

Sarraf P, Frederich RC, Turner EM, Ma G, Jaskowiak NT, Rivet DJ 3rd, Flier JS, Lowell BB, Fraker DL, Alexander HR.

J Exp Med. 1997 Jan 6;185(1):171-5.

50.

Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARgamma.

Hu E, Kim JB, Sarraf P, Spiegelman BM.

Science. 1996 Dec 20;274(5295):2100-3.

PMID:
8953045

Supplemental Content

Loading ...
Support Center